Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non-randomized, Open-label, Multi-center, Phase I/II Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Copanlisib in Pediatric Patients With Relapsed/Refractory Solid Tumors or Lymphoma

NCT03458728 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT03458728
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03458728 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non-randomized, Open-label, Multi-center, Phase I/II Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Copanlisib in Pediatric Patients With Relapsed/Refractory Solid Tumors or Lymphoma
Lead sponsor
Bayer
Phase
Phase 1/2
Overall status
Terminated
Start date
April 30, 2018
Completion date
February 1, 2023
Enrollment
31 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

ewing sarcoma, neuroblastoma, osteosarcoma, relapsed or refractory solid tumors or lymphoma in children, rhabdomyosarcoma